The estimated Net Worth of Mark E Mcgovern is at least 304 千$ dollars as of 5 July 2016. Mark Mcgovern owns over 5,000 units of Esperion Therapeutics stock worth over 8,700$ and over the last 11 years he sold ESPR stock worth over 0$. In addition, he makes 295,000$ as Independent Director at Esperion Therapeutics.
Sign up
Mark McGovern ESPR stock SEC Form 4 insiders trading
Mark has made over 1 trades of the Esperion Therapeutics stock since 2016, according to the Form 4 filled with the SEC. Most recently he bought 5,000 units of ESPR stock worth 50,000$ on 5 July 2016.
The largest trade he's ever made was buying 5,000 units of Esperion Therapeutics stock on 5 July 2016 worth over 50,000$. On average, Mark trades about 455 units every 0 days since 2014. As of 5 July 2016 he still owns at least 5,000 units of Esperion Therapeutics stock.
You can see the complete history of Mark Mcgovern stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mark McGovern biography
Dr. Mark E. McGovern M.D. serves as Independent Director of the Company. He is a board-certified cardiologist with over 20 years of experience developing lipid regulating therapies, and since 2007, has served as a consultant to the pharmaceutical industry in cardiovascular and lipid regulation. Dr. McGovern spent 10 years, from 1997 to 2007, at Kos Pharmaceuticals, where he last served as Executive Vice President, Medical Affairs, and Chief Medical Officer, prior to its acquisition by Abbott Laboratories. Prior to joining Kos Pharmaceuticals, Dr. McGovern spent 11 years at Bristol-Myers Squibb (NYSE: BMY), from 1986 to 1997, in various capacities, including Executive Director, Heart Failure and Atherosclerosis Clinical Research. Dr. McGovern earned his Bachelor's degree summa cum laude from Princeton University and his medical degree from the University of Vermont. Dr. McGovern is a Fellow of the American College of Cardiology and the American College of Physicians, and has published extensively on lipid management and its role in the treatment of coronary heart disease. McGovern is qualified to serve as a member of our Board based on his broad experience in the industry in which we operate and his expertise in lipid regulating therapies.
What is the salary of Mark McGovern?
As the Independent Director of Esperion Therapeutics, the total compensation of Mark McGovern at Esperion Therapeutics is 295,000$. There are 11 executives at Esperion Therapeutics getting paid more, with Timothy Mayleben having the highest compensation of 1,080,850$.
How old is Mark McGovern?
Mark McGovern is 66, he's been the Independent Director of Esperion Therapeutics since 2014. There are 1 older and 14 younger executives at Esperion Therapeutics. The oldest executive at Esperion Therapeutics Inc. is Antonio Gotto, 84, who is the Independent Director.
What's Mark McGovern's mailing address?
Mark's mailing address filed with the SEC is C/O ESPERION THERAPEUTICS INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI, 48108.
Insiders trading at Esperion Therapeutics
Over the last 11 years, insiders at Esperion Therapeutics have traded over 197,978,412$ worth of Esperion Therapeutics stock and bought 6,755,593 units worth 134,445,709$ . The most active insiders traders include Patrick G Enright、Target N Vbb Biotech Ag Bio...、Nicole Vitullo. On average, Esperion Therapeutics executives and independent directors trade stock every 33 days with the average trade being worth of 145,621$. The most recent stock trade was executed by Eric Warren on 19 August 2024, trading 211 units of ESPR stock currently worth 411$.
What does Esperion Therapeutics do?
esperion therapeutics, inc. is a pharmaceutical company focused on developing and commercializing first-in-class, oral, ldl-c lowering therapies for the treatment of patients with hypercholesterolemia. etc-1002, the company's lead product candidate, is an inhibitor of atp citrate lyase, a well-characterized enzyme on the cholesterol biosynthesis pathway; the same pathway that includes hmg-coa reductase, the enzyme target of statins. the company has successfully completed its phase 1 and phase 2 development programs for etc-1002, and plans to initiate its etc-1002 phase 3 development program by the end of 2015. for more information, please visit www.esperion.com.
What does Esperion Therapeutics's logo look like?
Complete history of Mark Mcgovern stock trades at Esperion Therapeutics
Esperion Therapeutics executives and stock owners
Esperion Therapeutics executives and other stock owners filed with the SEC include:
-
Timothy Mayleben,
President, Chief Executive Officer, Director -
Mark Glickman,
Chief Commercial Officer -
Richard B. Bartram,
CFO & Corp. Sec. -
Tracy Woody,
Independent Director -
Sheldon L. Koenig,
Pres, CEO & Director -
Richard Bartram,
Chief Financial Officer -
Dr. JoAnne Micale Foody FACC, M.D.,
Chief Medical Officer -
Nicole Vitullo,
Lead Independent Director -
Jay Shepard,
Independent Director -
Daniel Janney,
Independent Director -
Jeffrey Berkowitz,
Director -
Mark McGovern,
Independent Director -
Antonio Gotto,
Independent Director -
Alan Fuhrman,
Independent Director -
Ashley Hall,
Chief Development Officer -
Eric J. Warren R.Ph.,
Chief Commercial Officer -
Betty Jean Swartz,
Chief Strategy Officer -
Benjamin O. Looker,
Gen. Counsel -
Jerry Penn,
Exec. Director of Managed Care -
Roberta Peterson,
Sr. Director of National Accounts -
April Seiler,
Sr. Director of Project Management -
Dr. Joanne Micale Foody FACC, M.D.,
Chief Medical Officer -
Renee Marotta,
Head of Marketing -
Keith F. Lenden,
VP of Corp. Devel. & Strategy -
Benjamin Church,
Head of Corp. Communications & Investor Relations -
Dr. Kenneth J. Fiorelli,
Chief Technical Operations Officer -
Patrick G Enright,
Director -
Gilbert S Omenn,
Director -
Dov A Md Goldstein,
Director -
Mary Mc Gowan,
Chief Medical Officer -
Scott Braunstein,
Director -
Roger S Newton,
Executive Chairman, CSO -
Seth H. Z. Fischer,
Director -
Capital, Llc Boxer Asset Ma...,
-
Target N Vbb Biotech Ag Bio...,
-
Partners Viii, L.P.Alta Par...,
-
Kathleen K Schoemaker,
10% owner -
Partners Viii, L.P. Alta,
10% owner -
Capital Ii Lpaisling Capita...,
-
Parters Vii L Pblair James ...,
-
Capital Partners, Llc Longi...,
-
Noah L. Rosenberg,
Chief Medical Officer -
James C Blair,
10% owner -
Parters Vii L P Domain,
10% owner -
Vii Associates Lp Dp,
10% owner -
Brian H Dovey,
10% owner -
Brian K Halak,
10% owner -
Jesse I Treu,
10% owner -
Louis G Lange,
Director -
Joanne M. Foody,
Chief Medical Officer -
Sheldon L. Koenig,
President and CEO -
Benjamin Looker,
General Counsel -
Eric Warren,
Chief Commercial Officer -
Stephen Rocamboli,
Director -
Benjamin Halladay,
Chief Financial Officer -
J Martin Carroll,
Director